Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 8/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7681285 | 0.91 | MEN1 (0.52) | PIN1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL7687306 | 0.91 | SMN1; SMN2 (0.49) | PIN1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL7685816 | 0.89 | LMNA (0.49) | PIN1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL7683793 | 0.87 | PIN1 (0.49) | PIN1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL7682983 | 0.87 | PIN1 (0.46) | PIN1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL7683028 | 0.87 | PIN1 (0.45) | PIN1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL7687815 | 0.87 | LMNA (0.49) | PIN1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL7688166 | 0.86 | PIN1 (0.48) | PIN1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL7681050 | 0.86 | PIN1 (0.44) | PIN1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL7687828 | 0.86 | PIN1 (0.48) | PIN1LMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6339089-B2 | ANTIHYPOXIC AGENTS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; VASOCONSTRICTION; REDUCES BLOOD PARTIAL PRESSURE OF CARBON DIOXIDE; RESPIRATORY DISORDERS; UNDER OXYGEN INHALATION TREATMENT | FUJIREBIO INC. (JP) | 2002-01-15 | — | — | US | disclosed |
| US-20010006969-A1 | PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME | FUJIREBIO INC. (FUJIREBIO KABUSHIKI KAISHA) (JP) | 2001-07-05 | — | — | US | disclosed |
| EP-0899263-A2 | Fused pyrimidine derivatives and medicaments thereof for a blood oxygen partial pressure amelioration | Fujirebio Inc. (JP) | 1999-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010006969-A1 | PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME | CYP11B2, CYP11B1, OAT | PIN1 3705/4885LMNA 1397/4885SMN1; SMN2 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.